Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00055227.xml
Nephrologie aktuell 2023; 27(09): 408-411
DOI: 10.1055/a-2083-9405
DOI: 10.1055/a-2083-9405
Expertentipp
Triangel oder Mahler-Hammer im Konzert von kardiovaskulären Risikofaktoren
Lipoprotein(a)
Wer einmal die 6. Sinfonie (1903/1904) von Gustav Mahler hört, wird sicherlich im 4. Satz dieses Musikstückes durch den Hammerschlag regelrecht erschüttert werden. Im Gegensatz dazu wirkt eine Triangel geradezu minimalistisch in der Dynamik dieses Musikstückes. Übertragen auf das Lipoprotein(a) (Lp(a)) bleibt es weiterhin unklar, wie ausgeprägt dieser Partikel bei jedem einzelnen Patienten atherosklerotische kardiovaskuläre Erkrankungen (ASCVD) induzieren kann bzw. wie ausgeprägt seine Rolle in der Pathogenese der Atherosklerose („atherosklerotisches Konzert“) tatsächlich ist.
Publication History
Article published online:
06 November 2023
© 2023. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Berg K. A New Serum Type System in Man--the Lp System. Acta Pathol Microbiol Scand 1963; 59: 369-382 DOI: 10.1111/j.1699-0463.1963.tb01808.x.
- 2 Berg K, Dahlen G, Frick MH. Lp(a) lipoprotein and pre-beta1-lipoprotein in patients with coronary heart disease. Clin Genet 1974; 06: 230-235 DOI: 10.1111/j.1399-0004.1974.tb00657.x.
- 3 Kostner GM, Avogaro P, Cazzolato G. et al Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 1981; 38: 51-61 DOI: 10.1016/0021-9150(81)90103-9.
- 4 Arsenault BJ, Kamstrup PR. Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective. Atherosclerosis 2022; 349: 7-16 DOI: 10.1016/j.atherosclerosis.2022.04.015.
- 5 Nordestgaard BG, Chapman MJ, Ray K. et al Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31: 2844-2853 DOI: 10.1093/eurheartj/ehq386.
- 6 Utermann G. The mysteries of lipoprotein(a). Science 1989; 246: 904-910 DOI: 10.1126/science.2530631.
- 7 Koschinsky ML, Kronenberg F. The long journey of lipoprotein(a) from cardiovascular curiosity to therapeutic target. Atherosclerosis 2022; 349: 1-6 DOI: 10.1016/j.atherosclerosis.2022.04.017.
- 8 Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993; 270: 2195-2199
- 9 Kamstrup PR, Benn M, Tybjaerg-Hansen A. et al Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 2008; 117: 176-184 DOI: 10.1161/CIRCULATIONAHA.107.715698.
- 10 Kronenberg F, Mora S, Stroes ESG. et al Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society. Atherosclerosis 2023; 374: 107-120 DOI: 10.1016/j.atherosclerosis.2023.04.012.
- 11 Schmidt K, Noureen A, Kronenberg F. et al Structure, function, and genetics of lipoprotein (a). J Lipid Res 2016; 57: 1339-1359 DOI: 10.1194/jlr.R067314.
- 12 Kronenberg F. Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill?. Atherosclerosis 2022; 349: 123-135 DOI: 10.1016/j.atherosclerosis.2022.04.008.
- 13 Koschinsky ML, Stroes ESG, Kronenberg F. Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factor. Pharmacol Res 2023; 194: 106843 DOI: 10.1016/j.phrs.2023.106843.
- 14 Marcovina SM.. Lipoprotein(a): a genetically determined risk factor for Cardiovascular disease. Crit Rev Clin Lab Sci. 2023 Jul 14 1-13 DOI: 10.1080/10408363.2023.2229915 [Online ahead of print]
- 15 Kronenberg F, Mora S, Stroes ESG. et al Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 2022; 43: 3925-3946 DOI: 10.1093/eurheartj/ehac361.
- 16 Mach F, Baigent C, Catapano AL. et al 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-188 DOI: 10.1093/eurheartj/ehz455.
- 17 de Boer LM, Hof MH, Wiegman A. et al Lipoprotein(a) levels from childhood to adulthood: Data in nearly 3,000 children who visited a pediatric lipid clinic. Atherosclerosis 2022; 349: 227-232 DOI: 10.1016/j.atherosclerosis.2022.03.004.
- 18 Raitakari O, Kartiosuo N, Pahkala K. et al Lipoprotein(a) in Youth and Prediction of Major Cardiovascular Outcomes in Adulthood. Circulation 2023; 147: 23-31 DOI: 10.1161/CIRCULATIONAHA.122.060667.
- 19 Alhomoud IS, Talasaz A, Mehta A. et al Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease: A Review of Current and Emerging Therapies. Pharmacotherapy. 2023 Jul 18 DOI: 10.1002/phar.2851 [Online ahead of print]
- 20 Malick WA, Goonewardena SN, Koenig W. et al Clinical Trial Design for Lipoprotein(a)-Lowering Therapies: JACC Focus Seminar 2/3. J Am Coll Cardiol 2023; 81: 1633-1645 DOI: 10.1016/j.jacc.2023.02.033.
- 21 Schatz U, Schettler VJJ, Julius U. [State of the art: lipoprotein apheresis]. Dtsch Med Wochenschr 2023; 148: e44-e54 DOI: 10.1055/a-1516-2761.